Biobrás was a pioneer in Brazil in pharmaceutical biotechnology, being founded by entrepreneurs in the 70s, who have invested in the production of biological substances extracted from plants and animals tissues, for use in pharmaceutical, food and textile industries.
In the late 70s, the Company entered into a joint venture with one of the worlds leading producers of insulin, for the local production of animal insulin. We emphasize that at that time the Company was already approved by the FDA (Food and Drug Administration - the American body responsible for food and medicine control) operating according to Good Manufacturing Practices, which were only implemented in Brazil in 2001 with ANVISA (National Health Surveillance Agency).
In the 80s and 90s, the Company acquired control of the joint venture; developed a recombinant human insulin production technology; and its intellectual property rights. It also conquered new markets, one of the few Brazilian companies that exported pharmaceutical products to over 20 countries in Europe, America and Asia.
In 2001, Biobrás was spun off with the creation of Biomm. The main researchers, the full insulin production know-how and other biopharmaceuticals products, the patents of the insulin production process and key business executives were transferred to Biomm.
Biomm was exclusively dedicated to technological development, licensing of its technology and restructuring to return to the market.
In 2012, the Company moved to the Bovespa+ segment for greater transparency in corporate governance and, in 2013, completed the capitalization process for the construction of the factory in Nova Lima, Minas Gerais.
Today, the company works to accelerate the entry of biopharmaceutical products into the Brazilian market and also seeks other business opportunities in order to offer the market a portfolio of innovative products.
Last Update on May 28, 2015